Cyclosporine metabolism and pharmacokinetics following intravenous and oral administration in the dog
- PMID: 3952805
- PMCID: PMC3000222
- DOI: 10.1097/00007890-198603000-00021
Cyclosporine metabolism and pharmacokinetics following intravenous and oral administration in the dog
Abstract
The influence of assay method on single dose cyclosporine (CsA) pharmacokinetics was studied in nine dogs receiving either i.v. or oral CsA. Samples were drawn from hepatic, portal, and systemic veins at various times after the dose and CsA levels were determined by radioimmunoassay (RIA) and high-performance liquid chromatography (HPLC). Blood concentration-time data were analyzed by nonlinear least-squares regression, using two-compartment models. RIA/HPLC ratios for all samples were greater than one, and did not change significantly over time. The mean RIA/HPLC ratios for samples drawn from all three veins were higher after oral than i.v. doses of the drug (P less than 0.05). Area under the concentration-time curve (AUC) was higher and systemic clearance (CIs) lower than calculated on the basis of RIA results, regardless of the route of administration. AUC calculated for CsA metabolites (RIA-HPLC) was highest in the portal vein after an oral dose of CsA. Bioavailability was 20.4% and 27.0% when estimated using HPLC and RIA data, respectively. The mean CsA metabolite index (CMI), when calculated for hepatic, portal, or systemic vein, was greater when the drug was administered orally. The mean hepatic extraction ratio (HER) of the parent drug and for CsA metabolites was approximately 23% in i.v. and p.o. studies. These results suggest that the gastrointestinal tract may play a role in the metabolism of CsA when the drug is administered orally. In addition, if CsA metabolites not measured by HPLC have either toxic or immunosuppressive properties, the RIA assay may be more useful for monitoring patients.
Figures


Similar articles
-
Cyclosporine disposition in the dog. Comparison of radioimmunoassay with high-performance liquid chromatographic assay and pharmacokinetics following intravenous administration.Transplantation. 1985 Nov;40(5):483-8. Transplantation. 1985. PMID: 4060219
-
The potential replacement of HPLC by 125I-RIA for the characterization of cyclosporin A: a bioavailability study after oral administration in healthy human subjects.J Pharm Biomed Anal. 2000 Feb;22(1):183-8. doi: 10.1016/s0731-7085(99)00257-5. J Pharm Biomed Anal. 2000. PMID: 10727138 Clinical Trial.
-
Significant discrepancy in cyclosporin A post-dose concentrations when analyzed with specific RIA and HPLC method.Int J Clin Pharmacol Ther. 2010 Feb;48(2):87-92. doi: 10.5414/cpp48087. Int J Clin Pharmacol Ther. 2010. PMID: 20137760
-
Cyclosporine kinetics in renal transplant patients as assessed by high-performance liquid chromatography and radioimmunoassay using monoclonal and polyclonal antibodies.Transplantation. 1989 May;47(5):802-6. doi: 10.1097/00007890-198905000-00011. Transplantation. 1989. PMID: 2655217
-
Clinical pharmacokinetics of cyclosporin.Clin Pharmacokinet. 1986 Mar-Apr;11(2):107-32. doi: 10.2165/00003088-198611020-00002. Clin Pharmacokinet. 1986. PMID: 3514043 Review.
Cited by
-
Evidence for pre-hepatic metabolism of oral cyclosporine in children.Br J Clin Pharmacol. 1991 Oct;32(4):477-81. doi: 10.1111/j.1365-2125.1991.tb03934.x. Br J Clin Pharmacol. 1991. PMID: 1958443 Free PMC article.
-
Cyclosporine pharmacokinetics in liver transplant recipients: evaluation of results using both polyclonal radioimmunoassay and liquid chromatographic analysis.Eur J Clin Pharmacol. 1991;40(5):513-9. doi: 10.1007/BF00315232. Eur J Clin Pharmacol. 1991. PMID: 1884727
-
Drug absorption in gastrointestinal disease and surgery. Clinical pharmacokinetic and therapeutic implications.Clin Pharmacokinet. 1991 Dec;21(6):431-47. doi: 10.2165/00003088-199121060-00004. Clin Pharmacokinet. 1991. PMID: 1782738 Review.
-
Chronopharmacokinetics of Cyclosporine A in the Wistar rat following oral administration.Eur J Drug Metab Pharmacokinet. 1992 Apr-Jun;17(2):135-44. doi: 10.1007/BF03188782. Eur J Drug Metab Pharmacokinet. 1992. PMID: 1425812
-
Progression of cyclosporine A-blood levels in experimental cats receiving a high-dose treatment protocol.Front Vet Sci. 2024 Oct 16;11:1444586. doi: 10.3389/fvets.2024.1444586. eCollection 2024. Front Vet Sci. 2024. PMID: 39479202 Free PMC article.
References
-
- Elliott JF, Lin Y, Mizel SB, Bleackley RC, Harnish DG, Paetkan V. Induction of Interleukin 2 messenger RNA inhibited by cyclosporin A. Science. 1984;226:1439. - PubMed
-
- Britton S, Palacios R. Cyclosporin A: Usefulness, risks and mechanism of action. Immunol Rev. 1982;65:5. - PubMed
-
- Kahan BD, Ried M, Newburger J. Pharmacokinetics of cyclosporine in human renal transplantation. Transplant Proc. 1983;15:446.
-
- Kekown PA, Stiller CR, Laupacis AL, et al. The effects and side effects of cyclosporine: relationship to drug pharmacokinetics. Transplant Proc. 1983;14:659. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources